Gisselbrecht C, Lepage E, Brice P, Trédaniel J, Gerota I
Institut d'Hématologie, Hôpital Saint-Louis, Paris, France.
Nouv Rev Fr Hematol (1978). 1988;30(1-2):131-4.
The therapeutic approach to relapses in aggressive non-Hodgkin's lymphoma has been changed by high dose chemotherapy and autologous bone marrow graft. In the absence of dramatic improvement following the conditioning regimen, such a procedure should be reserved for patients still sensitive to salvage therapy. Up to 40%-50% of these selected cases can expect prolonged disease-free survival. Autologous bone marrow graft in first remission should only be considered in poor prognosis patients in a carefully randomized study. In Hodgkin's disease, relapses and patients in partial remission after MOPP and ABVD treatment are potential candidates for autologous bone marrow graft. Preliminary results indicate a disease-free survival up to 50%.
大剂量化疗和自体骨髓移植改变了侵袭性非霍奇金淋巴瘤复发的治疗方法。如果在预处理方案后没有显著改善，这种治疗方法应仅用于对挽救性治疗仍敏感的患者。这些经选择的病例中，高达40%-50%的患者有望获得延长的无病生存期。仅在经过精心设计的随机研究中，对于预后不良的患者，才应考虑在首次缓解期进行自体骨髓移植。在霍奇金病中，MOPP和ABVD治疗后复发以及部分缓解的患者是自体骨髓移植的潜在候选者。初步结果表明无病生存期可达50%。
